All Outputs (8)

The incidence and determinants of metabolic syndrome amongst a group of migrants to Qatar: a prospective longitudinal observational cohort study 24-months post-migration. (2021)
Journal Article
AL-ADAWI, R.M., PRABHU, K.S., STEWART, D., RYAN, C., ABDELAZIZ, H., ELEDRISI, M., IBRAHIM, M.I.M., UDDIN, S. and TONNA, A.P. 2022. The incidence and determinants of metabolic syndrome amongst a group of migrants to Qatar: a prospective longitudinal observational cohort study 24-months post-migration. Journal of clinical medicine [online], 11(1), article 34. Available from: https://doi.org/10.3390/jcm11010034

While there is some evidence that migration to Western countries increases metabolic syndrome (MetS) risk, there is a lack of data pertaining to migration to the Middle East. This study aimed to investigate the relationship between migration and MetS... Read More about The incidence and determinants of metabolic syndrome amongst a group of migrants to Qatar: a prospective longitudinal observational cohort study 24-months post-migration..

Incidence of co-trimoxazole-induced hyperkalemia in a tertiary care hospital. (2021)
Journal Article
AL ADAWI, R.M., ALBU-MAHMOOD, Z., ABDELGELIL, M., ABDELAZIZ, H., STEWART, D. and AWAISU, A. 2021. Incidence of co-trimoxazole-induced hyperkalemia in a tertiary care hospital. Risk management and healthcare policy [online], 14, pages 519-525. Available from: https://doi.org/10.2147/RMHP.S283471

Co-trimoxazole is a broad-spectrum antibiotic associated with hyperkalemia. To determine the incidence of hyperkalemia and its risk factors in patients receiving co-trimoxazole. A retrospective observational study involving all patients who received... Read More about Incidence of co-trimoxazole-induced hyperkalemia in a tertiary care hospital..

A systematic review of pharmacist input to metabolic syndrome screening, management and prevention. (2020)
Journal Article
AL ADAWI, R.M., STEWART, D., RYAN, C. and TONNA, A. 2020. A systematic review of pharmacist input to metabolic syndrome screening, management and prevention. International journal of clinical pharmacy [online], 42(4), pages 995-1015. Available from: https://doi.org/10.1007/s11096-020-01084-3

Metabolic syndrome is a cluster of factors that increase the risk of cardiovascular disease and include: diabetes and prediabetes, abdominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol and high blood-pressure. However, t... Read More about A systematic review of pharmacist input to metabolic syndrome screening, management and prevention..

Evaluating the effectiveness of pneumococcal vaccines against hospitalization and intensive care unit admission in adults. (2019)
Journal Article
EL-BARDISSY, A.H.E., AL-ADAWI, R.M., SHIBLE, A.A., ALBU-MAHMOOD, Z., ELGAILY, D.E. and ABDELAZIZ, H. 2019. Evaluating the effectiveness of pneumococcal vaccines against hospitalization and intensive care unit admission in adults. Journal of pharmaceutical health services research [online], 10(4), pages 427-431. Available from: https://doi.org/10.1111/jphs.12321

Objective: To evaluate the efficacy of pneumococcal vaccines concerning hospital or intensive care unit (ICU) admissions due to pneumonia after vaccination. Setting: Inpatient and ICUs at Hamad General Hospital. Methods: The retrospective study inclu... Read More about Evaluating the effectiveness of pneumococcal vaccines against hospitalization and intensive care unit admission in adults..

Critical appraisal of the clinical practice guideline for the management of dyslipidaemia and prevention of cardiovascular disease: AACE 2017 guidelines. (2019)
Journal Article
ALKHAWAJA, R.M., MADI, L., ALHAMOUD, E., ABDALLAH, I., JAVED, M., FAYEZ, H. and AL-ADAWI, R.M. 2019. Critical appraisal of the clinical practice guideline for the management of dyslipidaemia and prevention of cardiovascular disease: AACE 2017 guidelines. Journal of pharmaceutical health services research [online], 10(3), pages 383-388. Available from: https://doi.org/10.1111/jphs.12302

Objective: This study aims to appraise 2017 AACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease by using Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool. Method: A total of seven investigator... Read More about Critical appraisal of the clinical practice guideline for the management of dyslipidaemia and prevention of cardiovascular disease: AACE 2017 guidelines..

Assessment of dapagliflozin effectiveness as add-on therapy for the treatment of type 2 diabetes mellitus in a Qatari population. (2019)
Journal Article
AL ADAWI, R.M., JASSIM, Z., ELGAILY, D., ABDELAZIZ, H., SREE, B. and MOHAMED IBRAHIM, M.I. 2019. Assessment of dapagliflozin effectiveness as add-on therapy for the treatment of type 2 diabetes mellitus in a Qatari population. Scientific reports [online], 9, article 6864. Available from: https://doi.org/10.1038/s41598-019-43052-6

The effectiveness of dapagliflozin in the management of type-2 diabetes mellitus (T2-DM) is an essential issue for establishing a basis for prescribing dapagliflozin. This study aimed to assess the effectiveness of dapagliflozin in combination with o... Read More about Assessment of dapagliflozin effectiveness as add-on therapy for the treatment of type 2 diabetes mellitus in a Qatari population..

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. (2018)
Journal Article
ELEDRISI, M., SULEIMAN, N.N., SALAMEH, O., HAMAD, M.K., RABADI, O., MOHAMED, A., AL ADAWI, R. and SALAM, A. 2019. Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus. Journal of clinical and translational endocrinology [online], 15, pages 35-36. Available from: https://doi.org/10.1016/j.jcte.2018.12.002

Insulin glargine is recombinant human insulin analog that is commonly used in patients with type 2 diabetes as well as those with type 1 diabetes. Pharmacokinetic and pharmacodynamics studies of insulin glargine had shown that it has an onset of acti... Read More about Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus..

Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. (2018)
Journal Article
JASSIM, Z., ELAJEZ, R., KHUDAIR, I., AL ANANY, R., AL-ADAWI, R.M. 2019. Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study. Journal of pharmaceutical health services research [online], 10(1), pages 73-80. Available from: https://doi.org/10.1111/jphs.12240

Objective: Compare efficacy and safety of liraglutide (1.8 mg subcutaneous once daily) and exenatide (10 mcg subcutaneous twice daily) in uncontrolled type 2 diabetes at 26 and 52 weeks. Method: A retrospective observation study of uncontrolled type... Read More about Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients in Qatar: an observational study..